ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2515

The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis

Ruoning Ni1, Jessica L. Bloom2, Kaci Pickett-Nairne2, Lori Silveira3, Chao Zhang4, David Cuthbertson5, Thomas corbridge6, Nader Khalidi7, Curry Koening8, Carol McAlear9, Paul Monach10, Larry Moreland11, Christian Pagnoux12, Rennie Rhee9, Philip Seo13, Jared Silver6, Ulrich Specks14, Kenneth Warrington14, Michael Wechsler15, Carol Langford16, Peter Merkel9 and Rula Hajj-Ali1, 1Cleveland Clinic, Cleveland, 2University of Colorado, Denver, 3University of Colorado, Aurora, CO, 4Cleveland Clinic, Cleveland Heights, OH, 5University of South Florida, Tampa, 6US Medical Affairs Respiratory GSK, Durham, 7Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, 8University of Texas Dell Medical School, Austin, TX, 9University of Pennsylvania, Philadelphia, PA, 10VA Boston Healthcare System, Boston, MA, 11University of Colorado, Denver, CO, 12Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, 13Johns Hopkins University, Baltimore, MD, 14Mayo Clinic, Rochester, MN, 15Department of Medicine, National Jewish Health, Denver, 16Cleveland Clinic, Moreland Hills, OH

Meeting: ACR Convergence 2025

Keywords: ANCA associated vasculitis, Damage Index, neurology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2504–2523) Vasculitis – ANCA-Associated Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Neurologic involvement (NI) is common in ANCA-associated vasculitis (AAV) and often irreversible. It is unknown whether patients with AAV and NI accumulate more damage than those without NI. The objective of this study was to evaluate the association between NI and cumulative damage in patients with AAV.

Methods: Data from adults with granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA) participating from 2006 to 2021 in a multicenter longitudinal observational study were analyzed. Cohorts were divided by the presence of NI at any point in their disease course. Neurologic damage items (NDI) were classified as disease-specific (cranial nerve lesion, chronic pachymeningitis, neuropathy, and neuropathic pain) and non-disease specific (strokes, seizures, transverse myelitis, and neurologic mass). Group differences were tested using Kruskal-Wallis test for continuous variables and Fisher’s exact test for categorical. General and robust linear regression models were generated to estimate the differences in Vasculitis Damage Index (VDI), ANCA Vasculitis Index of Damage (AVID), AAV-Disease-Specific Damage (AAV-DSD), and AAV-Non-DSD scores. We also estimated the differences in AAV-DSD and Non-DSD scores with NDI removed. These models were adjusted for sex, age at diagnosis, and time from diagnosis to last damage assessment.

Results: Data from 1322 patients [65.9% GPA, 12.7% MPA, 21.4% EGPA] were analyzed: 526 (39.8%) had NI and 796 (60.2%) did not. Of those with ANCA results, 995 (75.3%) were ANCA positive (49.0% PR3-ANCA, 25.4% MPO-ANCA, 0.8% both). Older patients had more NI. Two-thirds of adults with EGPA had NI (Table 1). Among all AAV, patients with NI were estimated to have higher VDI (0.6 points; 95% CI: [0.35, 0.86], p < 0.0001), AVID (1.1 points; 95% CI: [0.66, 1.54], p < 0.0001), and AAV-DSD (0.91 points; 95% CI: [0.71, 1.12], p < 0.0001) scores than those without NI. The AAV-DSD score remained higher in those with NI even when NDI were removed. The AAV Non-DSD score was not different between NI groups. Among patients with GPA, those with NI had higher damage scores than those without, even with NDI removed. For MPA, those with NI only had higher AAV-DSD scores than those without. For EGPA, those with and without NI had no difference in scores. For both types of ANCA damage scores were higher among patients positive ANCA vs. those negative, even with NDI removed. Among patients negative for ANCA, those with NI only had higher AAV-DSD scores than those without (Table 2). Among patients with NI, those with GPA had more damage than those with MPA or EGPA. There were no differences in damage scores between PR3-ANCA, MPO-ANCA, and ANCA-negative groups (Table 3). Damage scores among patients with NI did not differ based on presence or absence of central vs. peripheral nervous system disease manifestations.

Conclusion: Patients with AAV and NI experience greater neurologic and non-neurologic cumulative damage than those without NI. The differences are driven by disease-specific items of damage. Of patients with NI, those with GPA, PR3-ANCA, or MPO-ANCA accumulate the most damage. These results highlight the importance and burden of NI in AAV.

Supporting image 1Characteristics of patients with ANCA-associated vasculitis stratified by neurologic involvement

Supporting image 2Differences in damage scores based on presence of neurologic involvement among all patients with AAV, AAV subtypes and ANCA status

Supporting image 3Differences in damage scores within subgroups among patients with ANCA-associated vasculitis and neurologic involvement based on disease subtypes and ANCA status.


Disclosures: R. Ni: None; J. Bloom: None; K. Pickett-Nairne: None; L. Silveira: None; C. Zhang: None; D. Cuthbertson: None; T. corbridge: GSK, 3, 11; N. Khalidi: AbbVie/Abbott, 2, 5, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 5, GlaxoSmithKlein(GSK), 2, 6, Mallinckrodt, 2, NS Pharma, 5, Otsuka, 2, 6, Roche, 2, 6, Sanofi, 2, 5; C. Koening: Amgen, 1, Boehringer-Ingelheim, 1; C. McAlear: None; P. Monach: Boehringer-Ingelheim, 2; L. Moreland: None; C. Pagnoux: amgen, 1, 2, 6, Astra zeneca, 1, 6, csl vifor, 1, 2, 6, gsk, 1, 2, 6, Novartis, 2, ns pharma, 1, otsuka, 1, 2, 5, 6, Pfizer, 2, 6; R. Rhee: None; P. Seo: None; J. Silver: Amgen, 3, GSK, 3; U. Specks: Amgen, 1, 2, 5, Argenx, 2, AstraZeneca, 1, 5, Boehringer-Ingelheim, 1, 2, Bristol-Myers Squibb(BMS), 5, CSL Vifor, 1, Genentech, 5, GlaxoSmithKlein(GSK), 5, Mayo Foundation for Education and Research, 9, Melodia Therapeutics, 2, NorthStar Medical Radioisotopes, 5, Novartis, 1, 2, 5, NS Pharma, 5, UpToDate, 9; K. Warrington: Bristol-Myers Squibb(BMS), 5, Sanofi, 2; M. Wechsler: allakos, 1, 2, 6, Amgen, 1, 2, 6, Areteia Therapeutics, 1, 2, 6, Arrowhead Pharmaceuticals, 1, 2, 6, AstraZeneca, 1, 2, 6, Avalo Therapeutics, 1, 2, 6, Celldex, 1, 2, 6, Connect Biopharma, 1, 2, 6, Eli Lilly, 1, 2, 6, Equillium, 1, 2, 6, GlaxoSmithKlein(GSK), 1, 2, 6, Incyte, 1, 2, 6, Kinaset, 1, 2, 6, Kymera, 1, 2, 6, Merck, 1, 2, 6, Phylaxis, 1, 2, 6, Pulmatrix, 1, 2, 6, Rapt Therapeutics, 1, 2, 6, Recludix Pharma, 1, 2, 6, Regeneron Pharmaceuticals, 1, 2, 6, Roche/Genentech, 1, 2, 6, Sanofi/Genzyme, 1, 2, 6, Sentien, 1, 2, 6, Sound Biologics, 1, 2, 6, Tetherex Pharmaceuticals, 1, 2, 6, Uniquity Bio, 1, 2, 6, Upstream Bio, 1, 2, 6, Verona Pharma, 1, 2, 6, Zurabio, 1, 2, 6; C. Langford: AbbVie/Abbott, 12, Non-paid consultant, AstraZeneca, 5, 12, Non-paid consultant, Bristol-Myers Squibb(BMS), 5, 12, Non-paid consultant, GlaxoSmithKlein(GSK), 5, NS Pharma, 5; P. Merkel: AbbVie, 2, 5, Alpine, 2, Amgen, 2, 5, ArGenx, 2, AstraZeneca, 2, 5, Boehringer-Ingelheim, 2, 5, Bristol-Myers Squibb (BMS), 2, 5, CSL Behring, 2, Eicos, 5, Electra, 5, GlaxoSmithKlein (GSK), 2, 5, iCell, 2, Interius, 2, Kinevant, 2, Kyverna, 2, 11, Lifordi, 11, Metagenomia, 2, Neutrolis, 2, 5, 11, Novartis, 2, NS Pharma, 2, Otsuka, 2, Q32, 2, 11, Quell, 2, Regeneron, 2, Sanofi, 2, Sparrow, 2, 11, Takeda, 2, 5, UpToDate, 9, Vistera, 2; R. Hajj-Ali: AbbVie/Abbott, 2, Amgen, 2, UpToDate, 9.

To cite this abstract in AMA style:

Ni R, Bloom J, Pickett-Nairne K, Silveira L, Zhang C, Cuthbertson D, corbridge T, Khalidi N, Koening C, McAlear C, Monach P, Moreland L, Pagnoux C, Rhee R, Seo P, Silver J, Specks U, Warrington K, Wechsler M, Langford C, Merkel P, Hajj-Ali R. The Association Between Neurologic Involvement and Cumulative Damage in ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-association-between-neurologic-involvement-and-cumulative-damage-in-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-between-neurologic-involvement-and-cumulative-damage-in-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology